Ownership and insider activity for AIM ImmunoTech Inc. (AIM): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States.
Price
| Price | $0.21 |
| Market Cap | $1M |
| Exchange | AMEX |
| Country | US |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.4M | $1.4M | $299000 | $1.5M | $38.5M | $32.1M | $27.1M | $5.4M | $1.7M | $931000 |
| Short-term Investments | $3.5M | $695000 | $1.5M | $7.3M | $501000 | $16.2M | $7.1M | $7.6M | $2.3M | $62000 |
| Receivables | 0 | $24000 | $1.1M | $820000 | $1.1M | $1.6M | $1.7M | $1.2M | 0 | $7000 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -$302000 | 0 | 0 |
| Total Current Assets | $6.9M | $3.5M | $3.8M | $10.4M | $40.3M | $50.2M | $36.3M | $14.6M | $4.2M | $3.3M |
| Property, Plant & Equipment | $9.5M | $8.6M | $7.8M | $7.3M | $6.7M | $4.2M | $1.0M | $824000 | $726000 | $449000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $872000 | $858000 | $912000 | $1.2M | $1.5M | $2.0M | $1.9M | $2.3M | $2.6M | $1.7M |
| Total Assets | $18.9M | $14.2M | $13.8M | $20.2M | $111.0M | $57.7M | $40.5M | $19.4M | $8.6M | $5.8M |
| Accounts Payable | $887000 | $741000 | $680000 | $472000 | $383000 | $198000 | $377000 | $6.4M | $6.4M | $1.6M |
| Short-term Debt | 0 | 0 | $3.6M | $214000 | $277000 | 0 | 0 | 0 | $2.3M | $3.8M |
| Total Current Liabilities | $2.4M | $2.7M | $5.3M | $1.1M | $1.1M | $673000 | $1.4M | $8.7M | $9.5M | $6.2M |
| Long-term Debt | 0 | $1.8M | 0 | $3.9M | 0 | 0 | 0 | 0 | 0 | $927000 |
| Total Liabilities | $3.4M | $5.5M | $8.7M | $7.3M | $49.7M | $820000 | $2.0M | $9.1M | $9.9M | $15.6M |
| Retained Earnings | -$300.5M | -$308.8M | -$318.6M | -$328.1M | -$342.0M | -$361.1M | -$380.5M | -$409.5M | -$426.8M | -$440.8M |
| Total Equity | $15.5M | $8.7M | $5.2M | $12.9M | $61.3M | $56.9M | $38.5M | $10.2M | -$1.3M | -$9.8M |
| Total Debt | 0 | $1.8M | $5.9M | $6.4M | $2.3M | $149000 | $837000 | $718000 | $2.9M | $4.9M |
| Net Debt | -$5.9M | -$272000 | $4.1M | -$2.4M | -$36.7M | -$48.1M | -$33.4M | -$12.4M | -$1.0M | $3.9M |
| Working Capital | $4.5M | $798000 | -$1.5M | $9.3M | $39.2M | $49.5M | $35.0M | $5.9M | -$5.4M | -$2.9M |
Financial Health
| Debt / Equity | 0.51 |
| Current Ratio | 2.11 |
Profitability
| Return on Equity | 952.76% |
| Return on Invested Capital | -94.78% |
| Return on Assets | -112.09% |
| Gross Margin | -125.26% |
| Operating Margin | -11637.89% |
| Net Margin | -15021.05% |
Related companies: CANF · ENSC · KALA · KTTA · OGEN · QNRX · SNGX
Explore sector: Healthcare · Biotechnology
More sections of AIM: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks